Ambu's new duodenoscope reaches over 98 percent success rate

Clinical testing of Ambu's improved duodenoscope, the Ascope Duodeno 1.5, continues to yield promising results, the medtech company reports on Monday.

Photo: PR / Ambu

Ambu has once again obtained positive results from clinical testing of its improved single-use duodenoscope, the Ascope Duodeno 1.5, it reports in a press release.

In connection with Ambu's results from the finanical year 2020/2021, which were announced in early November, the medtech company announced that 29 people had tested the Ascope Duodeno 1.5, with a success rate of 100 percent.

Read the whole article

Get 14 days free access.
No credit card required.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

"Real world" patient data documents the long-term effects of ALK vaccines

In the largest study ever of its kind, patient data from the "real world" documents the long-term effects of up to nine years of ALK vaccines. Up until now, it has not been possible to demonstrate these in ordinary clinical studies where the follow-up period is shorter, and the new knowledge could be a turning point in ALK's dialog about prices and subsidies with authorities and payers. 

Further reading

Related articles

Latest news

See all jobs